Robert Casey actually said...

the financial realities of developing these new agents remain very challenging.

key among these challenges is reaching agreement with regulators about determining the appropriate efficacy endpoints to support approval of...

antimicrobial resistance is a public health crisis, and no single solution is going to fix the problem.

We need creative ideas that can realign current market incentives to encourage drug developers to stay in this business.